Featured Articles

  1. What Does 2025 Hold For Pharma? 1/17/2025

    Look at what’s in store for pharma and life science in 2025. While we see many recurring themes, 2025 promises to be filled with unexpected — and possibly unprecedented — developments.

  2. Top 10 Tips For Diversity Plans 12/13/2024

    Explore the updated guidance from the FDA to enhance diversity in clinical trials, including ten times to developing a comprehensive Diversity Action Plans.

  3. Artificial Intelligence Regulation 12/13/2024

    To make the best use of artificial intelligence (AI), drug sponsors need to understand where health authorities are drawing the lines.

  4. Ensuring A Diverse Patient Population In Clinical Trials 12/13/2024

    In 2025, the FDA will require pharmaceutical companies to include diversity action plans (DAPs) for Phase II and pivotal studies.

  5. Practical Strategies For Diverse Trial Recruitment 11/11/2024

    The clock is ticking on the requirement for pharmaceutical companies to include FDA-mandated diversity action plans for pivotal studies in clinical trials.

  6. Maturity Model For Clinical Trial Disclosure 11/11/2024

    Learn about the eight key domains that are assessed by the clinical trial disclosure maturity model.

  7. Transforming Clinical Trial Disclosure With AI 10/23/2024

    Unlock the full potential of AI to address sponsor challenges including regulatory complexity, clinical trial disclosure requirements, and growing demands for transparency.

  8. AI in Pharma: Benefits, Risks, And The Road Ahead 10/23/2024

    How could leveraging AI technologies, including machine learning (ML) and generative AI (GenAI), enable your company to streamline processes from drug discovery to post-launch?

  9. A Promising Rebound in Clinical Trials 10/23/2024

    This report explores how clinical trials bounced back in 2023 from their decline a year earlier despite continued geopolitical, regulatory, and pricing pressures.

  10. The Importance Of A Maturity Model For Clinical Trial Transparency 10/23/2024

    A comprehensive maturity model for clinical trial disclosure and transparency offers companies a strategic tool to assess and enhance their practices in an increasingly complex regulatory environment.